Literature DB >> 11437468

The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration.

F Bauss1, K Lang, C Dony, L Kling.   

Abstract

The influence of recombinant human insulin-like growth factor-I (rhIGF-I), its binding protein-5 (IGFBP-5) or their equimolar complexes on calvarial osteogenesis was investigated by quantitative radiography and histomorphometry after local administration to adult mice or mature rats. The systemic effects of these proteins were investigated in aged Sprague-Dawley rats with regard to their ability to prevent or restore bone mass in ovariectomy induced osteopenia as assessed by radiography, dual-energy X-ray absorptiometry (DEXA) analyses, peripheral computerized tomography (pQCT) and mineral analyses after daily s.c. administration for 3 or 8 weeks following a bone depletion period of 8 weeks. Bone mass of murine calvariae was significantly increased in a dose-dependent manner by the complex 7 days after discontinuation of local administration for 19 days in mice, whereas IGF-I alone expressed only weak effects. IGFBP-5 alone was ineffective in this respect. In the same model, only the complex had a weak osteogenetic potential in 7 week or 5 month old rats. Systemic long-term treatment with the complex of rhIGF-I/IGFBP-5 (2.0/7.6 mg/kg/day, s.c.) for 8 weeks resulted in significantly increased cortical thickness, area and mineral density in femoral midshaft or tibial metaphysis suggesting periosteal bone formation. This was obviously related to increased muscle strength since these effects were parallelled by increased body weight. No effect on trabecular bone occurred as demonstrated by site-specific analyses (vertebrae, proximal tibia) using DEXA, pQCT and radiography. This selective action of rhIGF-I/IGFBP-5 on periosteal bone formation is unique for an IGFBP. Femoral ash and calcium content, both corrected for tissue volume, increased slightly. However, when the increase in cortical thickness and bone mass was corrected for bone size, the effects are nearly abolished, suggesting an additional effect of bone growth. This potential deserves further evaluation in order to differentiate between effects on cortical bone via muscle strength and lack of efficacy on trabecular bone balance. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437468     DOI: 10.1054/ghir.2000.0181

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  11 in total

Review 1.  The multi-functional role of insulin-like growth factor binding proteins in bone.

Authors:  Kristen E Govoni; David J Baylink; Subburaman Mohan
Journal:  Pediatr Nephrol       Date:  2004-11-11       Impact factor: 3.714

2.  Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo.

Authors:  Xuezhong Qin; Jon E Wergedal; Mark Rehage; Kiet Tran; Jacqueline Newton; Paggie Lam; David J Baylink; Subburaman Mohan
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

3.  Nuclear factor I transcription factors regulate IGF binding protein 5 gene transcription in human osteoblasts.

Authors:  Laura A Pérez-Casellas; Xiaoying Wang; Kristy D Howard; Mark W Rehage; Donna D Strong; Thomas A Linkhart
Journal:  Biochim Biophys Acta       Date:  2008-09-10

4.  Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation.

Authors:  Yousef G Amaar; David J Baylink; Subburaman Mohan
Journal:  J Bone Miner Res       Date:  2005-03-14       Impact factor: 6.741

5.  Identification and characterization of novel IGFBP5 interacting protein: evidence IGFBP5-IP is a potential regulator of osteoblast cell proliferation.

Authors:  Yousef G Amaar; Blanca Tapia; Shin-Tai Chen; David J Baylink; Subburaman Mohan
Journal:  Am J Physiol Cell Physiol       Date:  2005-11-02       Impact factor: 4.249

6.  Regulation of insulin-like growth factor binding protein-5, four and a half lim-2, and a disintegrin and metalloprotease-9 expression in osteoblasts.

Authors:  K E Govoni; Y G Amaar; A Kramer; E Winter; D J Baylink; S Mohan
Journal:  Growth Horm IGF Res       Date:  2005-11-28       Impact factor: 2.372

Review 7.  Insulin-like growth factor binding protein-5 in osteogenesis: facilitator or inhibitor?

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Growth Horm IGF Res       Date:  2007-02-21       Impact factor: 2.372

8.  Mapping quantitative trait loci that influence serum insulin-like growth factor binding protein-5 levels in F2 mice (MRL/MpJ X SJL/J).

Authors:  Subburaman Mohan; Godfred Masinde; Xinmin Li; David J Baylink
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

9.  Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions.

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Mol Endocrinol       Date:  2008-02-21

Review 10.  Function of matrix IGF-1 in coupling bone resorption and formation.

Authors:  Janet L Crane; Xu Cao
Journal:  J Mol Med (Berl)       Date:  2013-09-26       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.